ESN cleer

ESN Cleer, established in 2018, is a clinical-stage biopharmaceutical company focusing on the development of treatments for heart disease. The company was founded by Leo De Bruin, who serves as Managing Director, and Johnny Feng, the Chief Operations Officer. The leadership team is spearheaded by Professor Andrew J. Stewart Coats, a globally recognized cardiologist who holds the position of Executive Chair of the Board. His extensive background in cardiology and successful entrepreneurial ventures in the biotech and pharmaceutical sectors provide significant direction for the company's strategy.

The firm's core activity revolves around repurposing existing drugs to create novel treatments for specific cardiomyopathies, which are significant causes of heart failure. This drug repurposing strategy aims to lower the risks, reduce costs, and shorten the regulatory timeline for commercialization. The company's lead candidate is ESNtx005, a repurposed orphan drug designed to treat Restrictive Cardiomyopathy (RCM), a rare disease currently lacking specific therapies. ESN Cleer has achieved a 99% purity level for ESNtx005 and has secured a Composition of Matter patent for its synthesis method.

ESN Cleer operates as an unlisted public company, a transition it made in 2020 to allow for broader investor access. Since its inception, the company has successfully raised over A$5 million in capital from various investors, including institutional funds and key opinion leaders in the medical field. The company's business model is centered on the clinical development and subsequent commercialization of its proprietary drug candidates. This involves establishing a network of global clinical and commercial partners. A key part of its growth strategy includes the development of companion diagnostics (CDx) to deliver personalized medicine, identifying specific patient groups who would benefit most from their treatments. Projections indicate a potential ASX listing or a merger and acquisition event from 2025 onwards.

Keywords: ESN Cleer, biopharmaceutical, heart failure, cardiomyopathy, repurposed drug, orphan drug, ESNtx005, Restrictive Cardiomyopathy, clinical trials, drug development, companion diagnostics, personalized medicine, Leo De Bruin, Andrew J. Stewart Coats, cardiovascular disease, drug discovery, intellectual property, unlisted public company, medical technology, venture capital